Downregulation of serum mi R-17 and mi R-106b levels in gastric cancer and benign gastric diseases

• Published in: 中国癌症研究：英文版 2014 (6), p.711-716
• Main Author: Qinghai Zeng Cuihong Jin Wenhang Chen Fang Xia Qi Wang Fan Fan Juan Du Yihang Guo Changwei Lin Kaiyan Yang Jingjing Li Xiaowei Peng Xiaorong Li Ke Cao
• Format: Article
• Language: English
• Subjects: RT-PCR; 微RNA; 清水; 疾病; 肿瘤标志物; 胃癌; 血清样品; 逆转录聚合酶链式反应
• ISSN: 1000-9604; 1993-0631

Altered micro RNA（mi RNA） associated with gastric cancer（GC） development and mi R-17 and mi R-106 b were differentially expressed in GC tissues. This study detected serum levels of mi R-17 and mi R-106 b expression in GC, benign gastric disease（BGD） and healthy controls to assess them as tumor markers for GC. Serum samples from 40 GC, 32 BGD（10 gastric ulcer, 14 gastric polyps, and 8 gastric ulcer with polyps） and 36 healthy individuals were subjected to quantitative reverse transcription polymerase chain reaction（q RT-PCR） analysis of mi R-17 and mi R-106 b expression. The data showed that the serum levels of mi R-17 and mi R-106 b were significantly reduced in healthy individuals and BGD patients compared to GC patients. There was a significant association of mi R-17 and mi R-106 b expression with age, but not with other clinicopathological features, such as gender, tumor differentiation, stage and lymphatic metastasis. Further analysis showed that, in discriminating GC patients from healthy controls, mi R-17 could yield a receiver-operating characteristic（ROC） area under the curve（AUC） of 0.879 with 80.6% sensitivity and 87.5% specificity and mi R-106 b could yield an AUC of 0.856 with 75.0% sensitivity and 92.5% specificity. The combined AUC of mi R-17 and mi R-106 b was 0.913 with 83.3% sensitivity and 87.5% specificity. Collectively, these data suggest that detection of serum mi R-17 and mi R-106 b levels should be further evaluated as novel non-invasive biomarkers in early GC detection and surveillance of disease progression.